Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.68 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.68 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.51 |
| ▸ | PPARD | Q03181 | 4/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926764 | 0.85 | PARP10 (0.51) | PARP10PARP15SCN9AFFAR1PPARD | |
| SCHEMBL22286235 | 0.84 | PARP10 (0.64) | PARP10PARP15SCN9AFFAR4FFAR1 | |
| SCHEMBL1856415 | 0.84 | PARP10 (0.64) | PARP10PARP15SCN9AFFAR4FFAR1 | |
| SCHEMBL29051180 | 0.83 | PARP10 (0.52) | PARP10PARP15SCN9AFFAR1RARA | |
| SCHEMBL29051173 | 0.83 | PARP10 (0.52) | PARP10PARP15SCN9AFFAR1RARA | |
| SCHEMBL29051172 | 0.83 | PARP10 (0.52) | PARP10PARP15SCN9AFFAR1RARA | |
| SCHEMBL29051124 | 0.82 | ALDH1A1 (0.51) | PARP10PARP15SCN9AFFAR1RARA | |
| SCHEMBL29051126 | 0.82 | ALDH1A1 (0.51) | PARP10PARP15SCN9AFFAR1RARA | |
| SCHEMBL927718 | 0.82 | PARP10 (0.61) | PARP10PARP15SCN9AFFAR4FFAR1 | |
| SCHEMBL15969380 | 0.82 | PARP10 (0.50) | PARP10PARP15PARP2KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| CN-103998432-A | Bicyclic compounds | TAKEDA PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| WO-2009123194-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | PARP10 3035/4885PARP15 2382/4885SCN9A 3224/4885 |
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | PARP10 1776/4885PARP15 2724/4885SCN9A 3914/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | PARP10 3280/4885PARP15 1936/4885SCN9A 1166/4885 |
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | PARP10 4541/4885PARP15 4553/4885SCN9A 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.